Study on relationships of <italic style="font-style: italic">MS4A1</italic> gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma

SHI Feng; LIU Tao; HUANG He; FANG Caifu; GUAN Shaoxing; ZHANG Zhang; WANG Zhao; FANG Xiaojie; CHEN Zhuojia; LIU Shu

doi:10.6039/j.issn.1001-0408.2025.13.15

您当前的位置：

首页 >

文章列表页 >

Study on relationships of MS4A1 gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma

更新时间：2025-09-24

- Study on relationships of MS4A1 gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma
- ZHONGGUO YAOFANG Vol. 36, Issue 13, Pages: 1641-1647(2025)
- 作者机构：
  
  1.中山大学肿瘤防治中心药学部，广州　510060
  2.中山大学药学院，广州　510006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.13.15
  CLC： R969.4;R979.1
- Received：17 February 2025，
  
  Revised：2025-06-29，
  
  Accepted：30 June 2025，
  
  Published：15 July 2025
- 稿件说明：
移动端阅览
石凤,刘韬,黄河,等.非霍奇金淋巴瘤患者MS4A1基因多态性与利妥昔单抗血药浓度及疗效的相关性研究[J].中国药房,2025,36(13):1641-1647.

SHI Feng,LIU Tao,HUANG He,et al.Study on relationships of MS4A1 gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma[J].ZHONGGUO YAOFANG,2025,36(13):1641-1647.
石凤,刘韬,黄河,等.非霍奇金淋巴瘤患者MS4A1基因多态性与利妥昔单抗血药浓度及疗效的相关性研究[J].中国药房,2025,36(13):1641-1647. DOI： 10.6039/j.issn.1001-0408.2025.13.15.

SHI Feng,LIU Tao,HUANG He,et al.Study on relationships of MS4A1 gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma[J].ZHONGGUO YAOFANG,2025,36(13):1641-1647. DOI： 10.6039/j.issn.1001-0408.2025.13.15.

摘要

目的

探索非霍奇金淋巴瘤患者

MS4A1

基因多态性对利妥昔单抗血药浓度及疗效的影响。

方法

选择2016年1月至2020年12月在中山大学肿瘤防治中心接受R-CHOP方案的新确诊非霍奇金淋巴瘤患者160例进行前瞻性观察性研究，最短随访时间约5年。以酶联免疫吸附试验测定患者利妥昔单抗血药浓度。采用Haploview 4.2软件挑选

MS4A1

基因位点：rs1051461、rs17155034、rs4939364、rs10501385，以基质辅助激光解吸电离-飞行时间质谱法分析患者的基因型。采用单因素线性回归分析患者各因素（人口统计学、临床指标与基因型）与第1个疗程利妥昔单抗稳态谷浓度的相关性，并进行多元线性回归分析。绘制Kaplan-Meier曲线以评估患者的无进展生存期（PFS）和总生存期（OS）。以

MS4A1

基因型和肿瘤分期为自变量，采用Cox回归模型评估影响患者预后的因素。

结果

携带

MS4A1

rs10501385 CC基因型患者的利妥昔单抗血药浓度为15.20 μg/mL，显著低于AA+AC型患者的21.95 μg/mL（

＜0.05）。以患者肿瘤分期和

MS4A1

rs10501385基因多态性建立的利妥昔单抗血药浓度多元线性回归模型能解释7.3%的个体差异。与携带

MS4A1

rs1051461 CC基因型患者比较，CT+TT基因型患者的PFS和OS均显著延长（

＜0.05）。Cox回归模型显示，

MS4A1

rs1051461 CC基因型（HR＝4.406，95%CI为1.743～11.137，

＜0.05）和肿瘤分期Ⅲ或Ⅳ期（HR＝3.233，95%CI为1.413～7.399，

＜0.05）是影响患者PFS的独立危险因素。

结论

非霍奇金淋巴瘤患者的肿瘤分期和

MS4A1

rs10501385位点多态性是

利妥昔单抗血药浓度的关键影响因素，而肿瘤分期和

MS4A1

rs1051461位点多态性能显著影响非霍奇金淋巴瘤患者的PFS。

Abstract

OBJECTIVE

To explore the effects of CD20 coding gene （

MS4A1

） polymorphism on the blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma.

METHODS

A prospective observational study was conducted on 160 newly diagnosed non-Hodgkin’s lymphoma patients who received the R-CHOP regimen at the Sun Yat Sen University Cancer Center from January 2016 to December 2020， with a minimum follow-up period of approximately 5 years. The blood concentration of rituximab was detected by enzyme-linked immunosorbent assay.

MS4A1

tagSNPs were selected by Haploview4.2 software， including rs1051461， rs17155034， rs4939364， and rs10501385. The genotype of

MS4A1

was detected by Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Univariate linear regression analysis was employed to examine the correlation between various factors（demographic， clinical， and genotypic variables） in patients and the steady-state trough concentration of rituximab during the first course of treatment， followed by multivariate linear regression analysis. Kaplan-Meier curves were drawn to evaluate progression-free survival （PFS） and overall survival （OS）. Using

MS4A1

genotype and tumor stage as independent variables， Cox regression model was employed to evaluate the factors influencing patient prognosis.

RESULTS

The blood concentration of rituximab in

MS4A1

rs10501385 CC carriers was 15.20 μg/mL，which was significantly lower than 21.95 μg/mL in AA+AC carriers （

＜0.05）. The multivariate linear regression model incorporating tumor stage and

MS4A1

rs10501385 polymorphism explained 7.3% of the interindividual variability in rituximab concentrations. Compared wi

MS4A1

rs1051461 CC carriers， CT+TT carriers had significantly prolonged PFS and OS （

＜0.05）. The Cox proportional hazards regression model showed that the

MS4A1

rs1051461 CC genotype （HR＝4.406， 95%CI：1.743-11.137，

＜0.05） and tumor Ⅲ

Ⅳ （HR＝3.233， 95%CI： 1.413-7.399，

＜0.05） were independent risk factors for PFS.

CONCLUSIONS

The tumor staging and

MS4A1

rs10501385 polymorphism are key influencing factors for blood concentration of rituximab， and

MS4A1

rs1051461 polymorphism significantly affects PFS in non-Hodgkin’s lymphoma patients.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

PAVLASOVA G ， MRAZ M . The regulation and function of CD20：an “Enigma” of B-cell biology and targeted therapy [J ] . Haematologica ， 2020 ， 105 （ 6 ）： 1494 - 1506 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南2024 [M ] . 北京：人民卫生出版社， 2024 ； 23 - 219 .

CHOI C H ， PARK Y H ， LIM J H ， et al . Prognostic implication of semi-quantitative immunohistochemical assessment of CD20 expression in diffuse large B-cell lymphoma [J ] . J Pathol Transl Med ， 2016 ， 50 （ 2 ）： 96 - 103 .

ZHANG L N ， WANG L ， FANG C ， et al . The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma [J ] . Leuk Lymphoma ， 2015 ， 56 （ 3 ）： 676 - 681 .

BERINSTEIN N L ， GRILLO-LÓPEZ A J ， WHITE C A ， et al . Association of serum Rituximab （IDEC-C2B8） concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma [J ] . Ann Oncol ， 1998 ， 9 （ 9 ）： 995 - 1001 .

LIU S ， HUANG H ， CHEN R X ， et al . Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2 [J ] . Acta Pharmacol Sin ， 2021 ， 42 （ 4 ）： 641 - 647 .

LIU S ， WANG Z ， CHEN R X ， et al . Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL：a loading dose is recommended to improve clinical outcomes [J ] . Clin Transl Sci ， 2022 ， 15 （ 3 ）： 680 - 690 .

石远凯，孙燕，刘彤华 . 中国恶性淋巴瘤诊疗规范：2015年版 [J ] . 中华肿瘤杂志， 2015 ， 37 （ 2 ）： 148 - 158 .

JÄGER U ， FRIDRIK M ， ZEITLINGER M ， et al . Ritu- ximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender，bone marrow infiltration and clinical response [J ] . Haematologica ， 2012 ， 97 （ 9 ）： 1431 - 1438 .

GOLAY J ， SEMENZATO G ， RAMBALDI A ， et al . Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics [J ] . MAbs ， 2013 ， 5 （ 6 ）： 826 - 837 .

TOUT M ， CASASNOVAS O ， MEIGNAN M ， et al . Ritu- ximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients：a Lymphoma Study Association report [J ] . Blood ， 2017 ， 129 （ 19 ）： 2616 - 2623 .

KAMATH A V . Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies [J ] . Drug Discov Today Technol ， 2016 ， 21/22 ： 75 - 83 .

LI J ， ZHI J G ， WENGER M ， et al . Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia [J ] . J Clin Pharmacol ， 2012 ， 52 （ 12 ）： 1918 - 1926 .

TOBINAI K ， IGARASHI T ， ITOH K ， et al . Japanese multicenter phase Ⅱ and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma [J ] . Ann Oncol ， 2004 ， 15 （ 5 ）： 821 - 830 .

CONNE B ， STUTZ A ， VASSALLI J D . The 3′ untranslated region of messenger RNA：a molecular “hotspot” for pathology [J ] . Nat Med ， 2000 ， 6 （ 6 ）： 637 - 641 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of the efficacy of immune checkpoint inhibitors in the treatment of NSCLC with different KRAS genotypes

Study on evaluation criteria for the quality of Chinese patent medicine purchased centrally by the Guangdong alliance

脑心通胶囊治疗血管性痴呆的疗效及对患者氧化应激指标影响的临床观察

疏血通注射液治疗急性脑梗死的临床观察

疏血通注射液与舒血宁注射液治疗急性缺血性脑卒中疗效的队列研究

Related Author

CHEN Wei

CHEN Jiayi

LIAO Wen

YU Junxian

CHEN Juliang

ZHANG Hui

LIN Huiyun

HU Ziwei

Related Institution

Dept. of Pharmacy， Beijing Friendship Hospital， Capital Medical University

Dept. of Pharmacy， Emergency General Hospital

School of Nursing， Capital Medical University

Dept. of Pharmacy， the Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Chinese Medicine

Dept. of Pharmacy， Zhuhai Hospital， Guangdong Provincial Hospital of Chinese Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Study on relationships of MS4A1 gene polymorphism with blood concentration and efficacy of rituximab in patients with non-Hodgkin’s lymphoma

DOI：10.6039/j.issn.1001-0408.2025.13.15

摘要

Abstract

关键词

Keywords

references